Against the backdrop of tightening regulatory requirements and routine data integrity audits, compliance validation of Manufacturing Execution Systems (MES) has become a core bottleneck in the digital transformation of pharmaceutical manufacturers. Held on June 29–30, the Chengdu Pharmaceutical Digitalization Seminar was jointly organized by Siemens and the International Society for Pharmaceutical Engineering (ISPE). As an officially certified professional engineering partner of Siemens, Wellthinic sent Eason Huo, Project Director of the Automation Division, to present a comprehensive practical solution entitled *Full Lifecycle Compliance Validation of MES Systems in the Pharmaceutical Industry*. He exchanged insights on prevalent compliance challenges with quality, production and digitalization executives, embarking on a new journey of intelligent digitalization for the pharmaceutical sector.

 The Compliance Cornerstone of Pharmaceutical Digitalization

• Acting as the central nervous system of pharmaceutical production, MES interconnects end-to-end business workflows including ERP and DCS. As a critical computerized system, it directly impacts pharmaceutical product quality and patient safety amid continuous updates to global regulatory frameworks.

• Internationally: Regulations such as FDA 21 CFR Part 11, EU GMP Annex 11 (to be updated in 2026), GAMP®5 and the new ISPE Validation 4.0 paradigm are shifting the regulatory mindset from one-off documentation-based validation to continuous data-driven compliance governance.

• Domestically: The NMPA has strengthened inspections focusing on electronic records, audit trails and the ALCOA+ principles of data integrity. Pharmaceutical enterprises face mounting pressure to implement validation throughout the entire lifecycle of MES deployment, modification and operation.

Common Pain Points in Project Implementation

During his presentation, Eason Huo pointed out that MES validation is not merely a final delivery phase of a project, but a dynamic management system spanning the full system lifecycle. Only by prioritizing risk management, adhering to regulatory requirements and leveraging intelligent tools to boost efficiency can manufacturers strike a balance between compliance and production performance.

• Risk assessments are often superficial, with insufficient test coverage for high-risk functions, frequently resulting in audit observations.

• Lack of technical enablers for ALCOA+ implementation, giving rise to prominent issues including data tampering, retrospective data entry and broken traceability chains.

• Fragmented IQ/OQ/PQ validation procedures and the absence of standardized closed-loop change management lead to uncontrolled validation status over the system’s service life.

• Conventional manual validation suffers from low efficiency and fails to accommodate iterative upgrades of intelligent and automated production lines.

Full Lifecycle Validation Solution

Built on expertise accumulated by Siemens’ original pharmaceutical engineering team, the solution delivers a standardized validation framework covering URS formulation through ongoing change maintenance. Compatible with Class 1/3/4/5 software categories, it adopts V-model end-to-end governance to address pharmaceutical companies’ CSV (Computerized System Validation) challenges in a one-stop manner.

• Risk-stratified Validation: In accordance with ICH Q9, three-dimensional tools including IRA, FMEA and HAZOP are deployed to accurately classify risk levels. Resources are concentrated on critical quality-related processes to eliminate redundant testing and generate audit-ready documentation.

• Standardized Closed-loop IQ/OQ/PQ:IQ verifies the complete hardware and software operating environment;OQ encompasses full-function testing, compliance verification and integration testing;PQ simulates full-scale production scenarios to validate high-concurrency operation and electronic batch record compliance.

• ALCOA++ Data Integrity Implementation: Aligned with the third-generation pharmaceutical regulatory standards, the framework adds traceability requirements to the nine core ALCOA+ principles, enabling end-to-end data traceability across interconnected multi-system digital environments.

• Controlled Continuous Change Management: A full closed-loop change workflow is established. Differentiated validation activities are implemented based on change severity to ensure sustained compliance after system upgrades.

• Intelligent Upgrade toward Validation 4.0: Benchmarked against the ISPE paradigm, RPA, AI and other automated tools are deployed alongside embedded cybersecurity controls and digital asset online management, substantially shortening validation lead times.

Jointly Consolidating the Foundation of Industry Quality and Compliance

Amid the wave of digital transformation, compliance serves as the bottom line for sustainable operation of pharmaceutical enterprises, while efficient validation acts as an accelerator for digital and intelligent initiatives. Wellthinic looks forward to in-depth discussions with pharmaceutical industry peers to tackle tough challenges in MES validation, seize opportunities brought by industrial transformation, and strengthen the quality and safety barriers of pharmaceutical manufacturing.